Evidence map›Paper›PMID 36688711›Full record

ArticleMicrobiology spectrum2023

Andreas F Haag, Lassi Liljeroos, Paolo Donato, Clarissa Pozzi, Tarcisio Brignoli, Matthew J Bottomley, Fabio Bagnoli, Isabel Delany

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Science advances · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Andreas F HaagGSK, Siena, Italy.ORCID 0000-0002-6783-0231
Lassi LiljeroosGSK, Siena, Italy.
Paolo DonatoGSK, Siena, Italy.
Clarissa PozziGSK, Siena, Italy.
Tarcisio BrignoliGSK, Siena, Italy.ORCID 0000-0003-4601-4080
Matthew J BottomleyGSK, Siena, Italy.
Fabio BagnoliGSK, Siena, Italy.
Isabel DelanyGSK, Siena, Italy.
Roche (Finland) · FIUniversity of Bristol · GBUniversity of St Andrews · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus is a clinically important bacterial pathogen that has become resistant to treatment with most routinely used antibiotics. Alternative strategies, such as vaccination and phage therapy, are therefore actively being investigated to prevent or combat staphylococcal infections. Vaccination requires that vaccine targets are expressed at sufficient quantities during infection so that they can be targeted by the host's immune system. While our knowledge of

Indexed as

Staphylococcal InfectionsVaccinesAnimalsBacterial ProteinsGene Expression ProfilingLeukocidinsMiceStaphylococcus aureusVirulence FactorsBacterial ProteinsLeukocidinsVaccinesVirulence Factorshigh-throughput qRT-PCRin vivo gene expressionleukocidinsStaphylococcus aureusStaphylococcus aureus vaccine

Identifiers

PMID36688711
PMCPMC9927290
OpenAlexW4317752012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.